ATI-1777 is under clinical development by Aclaris Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ATI-1777’s likelihood of approval (LoA) and phase transition for Atopic Dermatitis (Atopic Eczema) took place on 11 Jun 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ATI-1777 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ATI-1777 overview

ATI-1777 is under development for the treatment of atopic dermatitis. The drug candidate is administered topically. The drug candidates act by targeting JAK1 and JAK3 protein. It is being developed based on KINect, drug discovery platform. 

It was also under the development for the treatment of alopecia areata and vitiligo.

Aclaris Therapeutics overview

Aclaris Therapeutics is bio-pharmaceutical company focused on identifying, developing and commercializing small molecule therapies for immuno-inflammatory conditions. Its lead product, ESKATA is a proprietary formulation of high-concentration hydrogen peroxide topical solution prescribed for the treatment of raised seborrheic keratosis (SK). The company’s pipeline products include A-101, ATI-1777-oral JAK 1/3 inhibitor, ATI-501, ATI-450-oral MK2 pathway inhibitor, soft JAK inhibitor, ITK oral anti-IL17 and ITK topical anti-IL17.Aclaris Therapeutics’ pipeline products are used for the treatment of common warts, alopecia areata, androgenetic alopecia, psoriasis, arthritis, gangrenosum, inflammatory bowel disease and atopic dermatitis. The company also develops investigational drugs to treat skin and hair conditions. Aclaris Therapeutics is headquartered in Wayne, Pennsylvania, the US.

Quick View ATI-1777 LOA Data

Report Segments
  • Innovator
Drug Name
  • ATI-1777
Administration Pathway
  • Topical
Therapeutic Areas
  • Dermatology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.